Skip to content
Top Globe News – Lifestyle
Author:
Tvardi Therapeutics
Tvardi Therapeutics’ TTI-109 Phase 1 Study Confirms Prodrug Design, Improved Tolerability and Pharmacodynamic Evidence of STAT3 Target Engagement
July 7, 2026
Tvardi Therapeutics to Participate in Upcoming Investor Events
May 21, 2026
Tvardi Therapeutics Announces First Quarter 2026 Results and Provides Business Update
May 8, 2026
Tvardi Therapeutics to Participate in the Raymond James Biotech Innovation Symposium
April 2, 2026
Tvardi Therapeutics Announces Fourth Quarter and Full-Year 2025 Results and Provides Business Update
March 31, 2026